RxDoctor Payments Data

Paul Mirone

Family Medicine · Erie, PANPI 1043219850

Payments from drug & device makers

$1,382in general payments, 2019–2025

Across 38 payments — averaging $36.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$436
  • Pfizer$216
  • Novo Nordisk$139
  • Dexcom, Inc.$125
  • Amgen$114
  • Boehringer Ingelheim$103
  • plus $248 from 6 others

What the payments were for

  • Speaking & faculty fees$151%
  • Food & beverage$1,35598%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,382 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,736
Medicare patients
184
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$15,622
EliquisApixaban15$11,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,381
Gabapentin38$733
Albuterol Sulfate HfaAlbuterol Sulfate19$552
Estradiol (Once Weekly)Estradiol12$532
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$531
Nebivolol Hcl11$525
Omeprazole27$476
Rosuvastatin Calcium14$329
Levothyroxine Sodium34$295
CefuroximeCefuroxime Axetil20$264
Methylprednisolone44$261
Bumetanide12$253
Pantoprazole Sodium19$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$15,62211 claims
PfizerEliquis$216$11,78915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →